Overview

* Xeris Q3 product revenue grows 40% YoY to $74 mln, slightly missing estimates

* Recorlev revenue grew 109% YoY to $37 mln, driven by increased patient demand

* Company updates 2025 revenue guidance to $285-$290 mln, reflecting 42% growth at midpoint

Outlook

* Xeris Biopharma ( XERS ) updates 2025 revenue guidance to $285-$290 mln from $280-$290 mln

* Company focuses on executing strategy to sustain growth into 2026

Result Drivers

* RECORLEV DEMAND - Recorlev revenue grew 109% YoY to $37 mln, driven by increased patient demand

* GVOKE INVENTORY - Decrease in COGS due to reduced Gvoke inventory write-offs

* REVENUE GUIDANCE UPDATE - Co updates 2025 total revenue guidance to $285-$290 mln, reflecting 42% growth at midpoint

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Slight $74.06 $74.18

Product Miss* mln mln (5

Revenue Analysts

)

Q3 EPS

Q3 Net $621,000

Income

Q3 $6.73

Operatin mln

g Income

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Xeris Biopharma Holdings Inc ( XERS ) is $10.00, about 1.3% above its November 5 closing price of $9.87

* The stock recently traded at 76 times the next 12-month earnings vs. a P/E of 188 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)